Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 8/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13927967 | 1.00 | ROCK1 (0.49) | ROCK1ROCK2PRKXPRKCEPRKCD | |
| Hydrochloric Acid SCHEMBL4188753 | 0.99 | ROCK1 (0.48) | ROCK1ROCK2PRKXPRKCEPRKCD | |
| SCHEMBL4186945 | 0.93 | HTR1A (0.48) | ROCK1HTR1AMMP12PARP1GAA | |
| SCHEMBL13927893 | 0.93 | HTR1A (0.48) | ROCK1HTR1AMMP12PARP1GAA | |
| SCHEMBL5220761 | 0.93 | HTR1A (0.48) | ROCK1HTR1AMMP12PARP1GAA | |
| Hydrochloric Acid SCHEMBL4184405 | 0.92 | HTR1A (0.48) | ROCK1HTR1AMMP12PARP1GAA | |
| Hydrochloric Acid SCHEMBL4195942 | 0.92 | HTR1A (0.48) | ROCK1HTR1AMMP12PARP1GAA | |
| SCHEMBL5248767 | 0.85 | HTR1A (0.52) | ROCK1ROCK2PRKCDHTR1AMMP12 | |
| Hydrochloric Acid SCHEMBL4184444 | 0.84 | HTR1A (0.52) | ROCK1ROCK2PRKCDHTR1AMMP12 | |
| SCHEMBL5216722 | 0.81 | MAP2K1 (0.52) | HTR1AMMP12PARP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330460-B1 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-21 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | ROCK1 2691/4885ROCK2 3415/4885PRKX 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.